Secondary Hormone Therapy for Castration-Resistant Prostate Cancer

The majority of patients with systemic prostate cancer treated with androgen deprivation therapy (ADT) will develop castration-resistant prostate cancer (CRPC).
Source: Cancer Network - Category: Cancer & Oncology Source Type: news